Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415857 · ClinicalTrials.gov registry record · Phase 2
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00415857: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00415857 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00415857, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find out if using the PR1 peptide vaccine (PR1) without PEG-Intron® (interferon) or in combination with interferon can reduce or eliminate disease in patients who have CML that is in cytogenetic remission after treatment with imatinib mesylate, but who still have small amounts of disease able to be noticed (detected). Researchers want to see if giving low doses of interferon together with PR1 may make the vaccine more effective. The safety of treatment in this study will also be studied.
Interventions
- DRUG Imatinib
- DRUG GM-CSF
- DRUG Peginterferon alfa-2b
- BIOLOGICAL Peptide Vaccine (PR1 Peptide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00415857
The ClinicalTrials.gov registry entry for NCT00415857 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Imatinib is the first listed.
NCT00415857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00415857 about?
NCT00415857 is a clinical study titled "Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)". The goal of this clinical research study is to find out if using the PR1 peptide vaccine (PR1) without PEG-Intron® (interferon) or in combination with interferon can reduce or eliminate disease in patients who have CML that is in cytogenetic remission after treatment with imatinib mesylate, but who ...
What is the current status of trial NCT00415857?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-12. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00415857?
The interventions under investigation include: Imatinib (DRUG), GM-CSF (DRUG), Peginterferon alfa-2b (DRUG), Peptide Vaccine (PR1 Peptide) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00415857?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.